Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.
Journal Information
Full Title: Neuroethics
Abbreviation: Neuroethics
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Medical Ethics
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interests Rik Vandenberghe (RV) is the principal investigator of the phase 1 and 2 studies with 18F–flutemetamol, an amyloid PET ligands approved for clinical use. RV has received consulting fees from GE Healthcare. RV’s institution has a clinical trial agreement with Merck, Eli Lilly, and Biogen (RV is the local PI). The sub-study reported here was part of the BioADadapt study, performed in collaboration with Janssen Pharmaceutical Company of Johnson and Johnson. The authors declare no other conflicts of interest."
"Funding This project was funded by the IWT (Agentschap voor Innovatie door Wetenschap en Technologie, Belgium). The project number is 120,836, and the title is, “Biomarker-Based Adaptive Development in AD.”"
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025